Biotech Investors Gamble On Ebola Stocks

The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.

Please Note: This content was released to our premium subscribers first. As we suspected might happen, Tekmira Pharmaceuticals (NASDAQ:TKMR) experienced a correction, dropping over 18% in value on Monday, while TapImmune Inc. (OTCQB:TPIV), which is rumored to be the next "Ebola stock" continued to trade under heavy volume and gained over 15% in value, making it one of the top percentage gainers in healthcare for the day. Below is the full text version of our article.:

The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more than constant media attention.

Several public companies like Inovio Pharmaceuticals Inc (NASDAQ:INO) and Hemispherx BioPharma (NYSEMKT:HEB) have thrown their hats into the ring to become part of the Ebola conversation, but Tekmira Pharmaceuticals (NASDAQ:TKMR) continues to perform well for investors day in and day out.

Actually, the developer of RNA interference (RNAi) therapeutics has become one of biotech’s best performing stocks since we first highlighted the firm as shares were trading at only $4.50, back in 2012. TKMR shares had seen a steady increase in value since that time, but we’ve seen that growth reach new levels since the firm’s own TKM-EBOLA was cleared for emergency use against Ebola in West Africa.

The company has announced it will join an international consortium that will establish clinical development centers in Ebola hot zones and Maxim’s analyst Jason Kolbert said that his firm has accelerated their Ebola assumptions and as a result sees additional upside in the stock.

1 2 3 4
View single page >> |

Disclosure: This article contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
John Fitch 6 years ago Member's comment

Great recommendations. Other stocks I would watch for would be Sarepta (SRPT) and Chimerix (CMRX). Sarepta has an experimental ebola vaccine and Chimerix was recently given FDA authorization for its drug brincidofovir. Brincidofovir was the drug used to treat the Texas man who had ebola.